As reported on Patentdocs Sandoz has filed for the Declaratory judgment of invalidity and non-infringement of U.S. Patent Nos. 6,126,971 ("Stable Oral CI-981 Formulation and Process for Preparing Same," issued October 3, 2000), 5,969,156 ("Crystalline [r- (R*,R*)]-2-(4-DFluorophenyl)-b,δ-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Corbonyl]-1HPyrrole-1Heptanoic Acid Hemi Calcium Salt (Atorvastatin)," issued October 19, 1999), and 5,686,104 ("Stable Oral CI-981 Formulation and Process of Preparing Same," issued November 11, 1997) based on Sandoz's filing of an ANDA to manufacture a generic version of Pfizer's Caduet®.
The details can be read here.
The complaint can be read here.
No comments:
Post a Comment